Key Drivers
- Q4 profitability
- High operating costs
- Strong gross margin
AIAI Summary
Evolv's strategic pivot to recurring ARR and direct purchases — evidenced by stadiums, hospitals, and improving quarterly cash/net income — reframes it as a potential high‑multiple software-like play, but the thesis is contingent on achieving Plexus-driven COGS reductions and converting RPO/deferred revenue into high-retention, cash-generating ARR. If manufacturing scale or renewal execution slips, the recent profitability is reversible and the richly priced stock leaves little margin for error.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Q4 profitability
- •High operating costs
- •Strong gross margin
EVLV shows a material turnaround in Q4 with positive net income and operating cash flow, but full-year losses, high SG&A-driven operating cash burn, large deferred revenue and heavy capex leave valuation elevated and risk materially intact.
Price Behavior
Key Price Behavior Insights:
- •Modest uptrend
- •Close to SMA
- •High short-term volatility
Over the last month EVLV has risen from $4.90 to $5.59, trading about 6% above its $5.26 SMA (short-term bullish) with nearest resistance at $5.75 and support clustered around $4.90–$5.11, though a volatile spike to $5.75 followed by a pullback raises execution risk.
Sharp spike to $5.75 then pullback indicates short-term volatility
Sentiment & News
Key News Insights:
- •Q4 EPS beat
- •Major deployments
- •Investor momentum
Evolv delivered a Q4 earnings beat and demonstrated accelerating commercial traction (4B screenings, stadium and healthcare wins) alongside rising investor interest and a planned Investor Day, signaling improving fundamentals and upside potential.
Positive operational momentum and clearer growth visibility should support EVLV stock sentiment and potential upside, though execution and market follow‑through risks remain
Similar Companies in Industrials
Other companies in the same sector with AI ratings